Cancer Diagnostics – News and Features

Researchers from around the UK, led by the University of Oxford, have found that a new way of performing prostate biopsies is better at diagnosing prostate cancer, but takes longer to perform and is more painful for patients.

New research from Mayo Clinic finds that the presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma.

This article explores 6-base genome sequencing and how it is empowering researchers to expand their studies to include both genetic and epigenetic data. 

A new approach to monitoring molecular processes deep in tissues could accelerate personalized medicine, cancer diagnostics and disease detection.

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors.

Researchers from the Wellcome Sanger Institute and partners found that genetic changes linked to neurofibromatosis type 1 (NF-1) appear in normal tissues, not just tumors. This challenges the belief that NF1 gene loss alone drives tumor formation.

A largescale study has found huge variation between GP practices on whether they are likely to pick up prostate cancer using a blood test.

Researchers at Rice University and Vanderbilt University found that combining focused ultrasound (FUS) with TRAIL protein therapy significantly reduces prostate tumor size in lab models. The treatment enhances cancer cell death via Piezo1 activation.

The burden of cancer isn’t distributed evenly across the population, with health inequalities causing unfair differences in cancer outcomes.

Researchers at Fred Hutch and MD Anderson discovered RNA Polymerase II on histone genes as a biomarker for cancer aggressiveness. Using CUTAC technology, they accurately predicted tumor severity and recurrence in meningioma and breast cancer.